At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 380 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.
In Brief
A Phase 3 clinical trial evaluating Metformin and Placebo for ST Elevation Myocardial Infarction (STEMI) and 3 related conditions. Completed, enrolled 380 participants across 1 site.
Detailed Summary
The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic resonance imaging, compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease, Heart Failure, Diabetes
CountriesNetherlands
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartJan 2011
Primary CompletionOct 2013
Study CompletionOct 2015
TodayJul 2026
First PostedOct 8, 2010
Enrollment StartJan 1, 2011
Primary CompletionOct 1, 2013
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.7 years ago
Interventions
Metformindrug
Metformin 500mg twice daily during 4 months
Placebodrug
Placebo twice daily during 4 months